Time for new indications for statins?

Medical Science Monitor

Volumn 15, Issue 12, 2009, Pages

  Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Kjeldsen, Sverre E ^c   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular disease; Chronic kidney disease; Hypertension; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; DYSLIPIDEMIA; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER FUNCTION TEST; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL;

EID: 75149185140     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Kovesdy CP, Kalantar-Zadeh K: Lipids in aging and chronic illness: impact on survival. Arch Med Sci, 2007; 3(4A): S74-80
2. Stepien M, Banach M, Mikhailidis DP et al: Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin, 2009; 25: 1995-2005
3. von Haehling S, Anker SD: Statins: much more than cholesterol reduction. Arch Med Sci, 2007; 3(4A): S67-68
4. Banach M, Goch JH, Ugurlucan M et al: Statins in the prevention of postoperative atrial fibrillation: is there really no effect? Am Heart J, 2008; 155(6): e53
5. Pletcher MJ, Lazar L, Bibbins-Domingo K et al: Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med, 2009; 150(4): 243-54
6. Roberts WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol, 1997; 80(1): 106-7
7. Höfer J, Niebauer J: Cardiovascular risk factors: lipids and lifestyle changes. Arch Med Sci, 2007; 3: S69-73
8. Aydin U, Ugurlucan M, Gungor F et al: Effects of Atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology, 2009; 60: 370-77
9. Koh KK, Quon MJ, Waclawiw MA: Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis, 2008; 196: 1-8
10. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP: Analysis of Antihypertensive Effects of Statins. Curr Hypert Rep, 2007; 9: 175-83
11. Tjugen TB, Halvorsen S, Bjørnerheim R, Kjeldsen SE: The role of statins in patients with arterial hypertension. Arch Med Sci, 2007; 3(4A): S97-101
12. Strazzullo P, Kerry SM, Barbato A et al: Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension, 2007; 49(4): 792-98
13. Messerli FH, Pinto L, Tang SS et al: Impact of systemic hypertension on the cardiovascular benefits of statin therapy - a meta-analysis. Am J Cardiol, 2008; 101: 319-25
14. Borghi C, Dormi A, Veronesi M et al: Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J, 2004; 148: 285-92
15. Williams B, Lacy PS, Cruickshank JK et al: Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation, 2009; 119(1): 53-61
16. Safar ME, Protogerou AD, Blacher J: Statins, central blood pressure, and blood pressure amplification. Circulation, 2009; 119(1): 9-12
17. Goch A, Banach M, Mikhailidis DP et al: Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens, 2009; 31(1): 20-30
18. Sandek A, Utchill S, Rauchhaus M: The endotoxin-lipoprotein hypothesis - an update. Arch Med Sci, 2007; 3: S81-90
19. Sposito AC, Mansur AP, Coelho OR et al: Additional reduction in blood pressure after cholesterol-lowering traetment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enelapril or lisinopril). Am J Cardiol, 1999; 83: 1497-99
20. Wang CY, Liao JK: Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci, 2007; 3: S91-96
21. Milionis HJ, Liberopoulos EN, Achimastos A et al: Statins: another class of antihypertensive agents? J Hum Hypertens, 2006; 20(5): 320-35
22. Manisty C, Mayet J, Tapp RJ et al: ASCOT Investigators. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension, 2009; 54(5): 1009-13
23. Mancia G, De Backer G, Dominiczak A et al: ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens, 2007; 25: 1751-62
24. Mancia G, Laurent S, Agabiti-Rosei E et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens, 2009; 27: 2121-58
25. Seliger SL, Weiss NS, Gillen DL et al: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int, 2002; 61(1): 297-304
26. Rysz J, Aronow WS, Stolarek RS et al: Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets, 2009; 13(5): 541-50
27. Dembowski E, Davidson MH: Role of statin therapy in the management of patients with the metabolic syndrome. Arch Med Sci, 2007; 3(4A): S102-8
28. Kanbay M, Turgut F, Covic A, Goldsmith D: Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol, 2009; 22(5): 598-609
29. Athyros VG, Mikhailidis DP, Liberopoulos EN et al: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant, 2007; 22(1): 118-27
30. Krane V, Winkler K, Drechsler C et al, German Diabetes and Dialysis Study Investigators: Effect of Atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int, 2008; 74(11): 1461-67
31. Fellström BC, Jardine AG, Schmieder RE et al: AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med, 2009; 360: 1395-407
32. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP: Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol, 2009; 7(3): 264-66
33. Strippoli GF, Craig JC: Sunset for statins after AURORA? N Engl J Med, 2009; 360(14): 1455-57
34. Szadkowska I, Stanczyk A, Aronow WS et al: Statin therapy in the elderly: A review. Arch Gerontol Geriatr, 2009; (in press)
35. Navaneethan SD, Nigwekar SU, Perkovic V et al: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev, 2009; 8(3): CD004289
36. Navaneethan SD, Pansini F, Perkovic V et al: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev, 2009; 15(2): CD007784
37. Kowalski J, Barylski M, Banach M et al: Neutrophil superoxide anion generation during Atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol, 2006; 48(4): 143-47
38. Krum H: Challenges in trials evaluating statins in heart failure. Arch Med Sci, 2007; 3: S142-46
39. Banach M, Drozdz J, Okonski P, Rysz J: Immunological aspects of the statins' function in patients with heart failure: a report from the Annual Conference of ESC - Heart Failure 2005. Cell Mol Immunol, 2005; 2(6): 433-37
40. von Haehling S, Anker SD: Statins for heart failure: where to go from here? Arch Med Sci, 2007; 3: S133-41
41. Rysz J, Mikhailidis DP, Banach M: Oxidative stress and atherosclerosis in chronic kidney disease. Arch Med Sci, 2009; 5(3A): S 415-20
42. Banach M, Mikhailidis DP, Ugurlucan M et al: The significance of statin use in patients subjected to surgical coronary revascularization. Arch Med Sci, 2007; 3: S126-30
43. Dawe DE, Ariyarajah V, Khadem A: Is there a role for statins in atrial fibrillation? Pacing Clin Electrophysiol, 2009; 32: 1063-72
44. Kostapanos MS, Liberopoulos EN, Goudevenos JA et al: Do statins have an antiarrhythmic activity? Cardiovasc Res, 2007; 75(1): 10-20
45. Sever PS, Poulter NR, Dahlof B et al: ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J, 2008; 29(4): 499-508
46. Efstratiadis G, Tziomalos K, Mikhailidis DP et al: Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol, 2008; 6(2): 93-107
47. Athyros VG, Kakafika AI, Papageorgiou AA et al: Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J, 2007; 1: 8-14
48. Koskinas K, Tzellos TG, Gougoulias K et al: Simvastatin-induced rhabdomyolysis: a case study on clinical-decision making based on the evidence-based medicine approach. Arch Med Sci, 2007; 3(3): 267-71